On June 26, 2024, Haleon plc announced the sale of its nicotine replacement therapy business outside the US to Dr. Reddy's for £500 million, which includes an upfront payment of £458 million and additional performance-related payments in 2025 and 2026. This divestment, which generated £217 million in net revenue for 2023, aims to streamline operations and focus on core growth areas.